Article: Service evaluation suggests variation in clinical care provision in adults with CAH in the UK and Ireland
The study, published March 2024, with two of the Group’s medical advisors (Faisal Ahmed & Nils Krone) and our Chair, Sue Elford as as some of the authors, concludes that:
“Differences in current management of CAH continue to exist. It appears crucial to objectify if different approaches result in different long-term outcomes. New studies such as CaHASE2, incorporating standardised minimum datasets including replacement therapies and monitoring strategies as well as longitudinal data collection, are now needed to define best-practice and standardise care.”
Read the full article here.
Recent Blog Posts
Patient Survey: Improving the Delivery of Genetic Results
CAH is a rare genetic condition and many of us will have received results of genetic testing at some point on our CAH journey. When you received these reults might not have been at the best time - pehaps you received genomic test results while you were driving, on...
Webinar: Finding Your Way – A Parent’s Guide to Rare Disease
Join the NHS South East Genomic Medicine Service and Unique on Wednesday 16th September 2026 at 12-1pm on Teams to celebrate the launch of “Finding Your Way: A Parent's Guide to Rare Disease”. Written by parents, for parents, this new guide offers practical support,...
New report highlights access gap for innovative medicines
The CAH Support Group recently provided input into a new Medicines Australia report about access to innovative medicines in Australia. The report, now published, warns that Australian patients are missing access to some innovative medicines available in comparable...